Maxim Group Initiates Coverage On FibroBiologics with Buy Rating, Announces Price Target of $12
Portfolio Pulse from Benzinga Newsdesk
Maxim Group has initiated coverage on FibroBiologics with a Buy rating and set a price target of $12.
September 24, 2024 | 12:59 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Maxim Group has initiated coverage on FibroBiologics with a Buy rating and a price target of $12, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $12 by Maxim Group suggests a positive sentiment towards FibroBiologics. This is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100